Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
metformin + simvastatin + fenofibrate
- Development stage
- Preclinical
- Lead developer
- Merck
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of metformin, simvastatin, and fenofibrate. Metformin is a biguanide antihyperglycemic agent that improves insulin sensitivity and reduces plasma fasting insulin levels. Simvastatin is an HMG-CoA reductase inhibitor that lowers LDL cholesterol and total cholesterol. Fenofibrate is a fibrate drug that primarily reduces triglycerides and increases HDL cholesterol levels. This triple combination targets multiple aspects of metabolic dysfunction in patients with type 2 diabetes and mixed dyslipidemia.
- Other names
- Metformin, Fenofibrate and Simvastatin combination
02
Targets
AMPK (Adenosine monophosphate–activated protein kinase)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PPARA (Peroxisome proliferator-activated receptor alpha)
Beyond the preview
Go deeper on metformin + simvastatin + fenofibrate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on metformin + simvastatin + fenofibrate.